NOVELSTEM INTERNATIONAL CORP. NovelStem International Corp. Share Price
Equities
NSTM
US67001V1098
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.06 USD | 0.00% |
|
0.00% | -4.61% |
| Sales 2022 | 0.01 0.96 | Sales 2023 | 0.01 0.96 | Capitalization | 2.95M 236M |
|---|---|---|---|---|---|
| Net income 2022 | - 0 | Net income 2023 | -4M -320M | EV / Sales 2022 | 757,203,750 x |
| Net Debt 2022 | 282K 22.56M | Net Debt 2023 | 3.52M 282M | EV / Sales 2023 | 539,198,333 x |
| P/E ratio 2022 |
-9.39
x | P/E ratio 2023 |
-0.7
x | Employees | 15 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 33.68% |
More Fundamentals
* Assessed data
More news
More press releases
| Current month | -14.29% | ||
| 1 month | -14.29% | ||
| 3 months | -24.05% | ||
| 6 months | -54.23% | ||
| Current year | -4.61% |
1 week
0.06
0.06
1 month
0.060.06
Current year
0.060.08
1 year
0.060.28
3 years
0.030.35
5 years
0.030.35
10 years
0.031.43
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 70 | 21/01/93 | |
| Director of Finance/CFO | 61 | 28/09/22 | |
Jan Loeb
CHM | Chairman | 65 | 30/06/18 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
David Seltzer
BRD | Director/Board Member | 64 | - |
| Founder | 70 | 21/01/93 | |
Jan Loeb
CHM | Chairman | 65 | 30/06/18 |
NovelStem International Corp. is a development-stage biotechnology holding company focused on stem cell-based technology. The Company's primary assets are NewStem Ltd (NewStem) and NetCo Partners (NetCo). NewStem focuses on the development and commercialization of diagnostic technology that can predict patientsâ anti-cancer drug resistance, allowing for targeted cancer treatments and the potential to reduce resistance to chemotherapy. NewStem is principally focused on utilizing proprietary human Pluripotent Stem Cells (hPSCs) and Haploid human Pluripotent Stem Cells (HhPSCs) in the development of diagnostic and therapeutic products in oncology. Its NewStem Software Diagnostic Device (NSDD) is a bioinformatics-based software medical device platform that provides oncologists with information regarding the presence of mutations in tumors, which may confer patient resistance to certain anti-cancer drugs. NetCo is a media business interest which owns Net Force, a book publishing franchise.
| 1st Jan change | Capi. | |
|---|---|---|
| -4.61% | 2.81M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- NSTM Stock
